SCHEMBL3082936

SCHEMBL3082936

NC(=O)c1ccc(OCCCCCl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP10 Q53GL7 7/20 0.66
▸ PRSS1 P07477 4/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ PRMT1 Q99873 3/20 0.55
▸ F2 P00734 2/20 0.55
▸ ST14 Q9Y5Y6 2/20 0.55
▸ TMPRSS2 O15393 2/20 0.55
▸ PLAU P00749 1/20 0.55
▸ GAA P10253 1/20 0.55
▸ PRMT5 O14744 1/20 0.55
▸ SLC22A2 O15244 1/20 0.55
▸ SLC22A1 O15245 1/20 0.55
▸ PTP4A3 O75365 1/20 0.55
▸ SLC22A3 O75751 1/20 0.55
▸ F10 P00742 1/20 0.55
▸ PLG P00747 1/20 0.55
▸ S100B P04271 1/20 0.55
▸ CHRM2 P08172 1/20 0.55
▸ CHRM4 P08173 1/20 0.55
▸ CHRM5 P08912 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1977030 0.94 PARP10 (0.68) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL3085074 0.91 PARP10 (0.68) PARP10PRSS1HRH3PARP15ALDH1A1
Water SCHEMBL5055924 0.87 PARP10 (0.68) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL1787654 0.86 PARP10 (0.62) PARP10PRSS1HRH3PARP15ALDH1A1
SCHEMBL17963079 0.84 PARP10 (0.64) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL4652513 0.84 PARP10 (0.64) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL4654822 0.84 PARP10 (0.64) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL4652331 0.84 PARP10 (0.64) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL27295340 0.84 PARP10 (0.64) PARP10PRSS1L3MBTL1PRMT1F2
SCHEMBL3986779 0.84 TP53 (0.70) PARP10L3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 — — US claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 — — EP claimed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 — — WO claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 — — US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 — — US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 — — EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR PARP10 4476/4885PRSS1 3959/4885L3MBTL1 1094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback